icon-avatar
Economía

COMUNICADO: Eisai y BIAL presentarán nuevos datos de investigación sobre Zebinix® en el congreso internacional de epilepsia (y 3)

    EISAI
    5.210,00+0,39%

    7 Soares-da-Silva P, Martins-da-Silva A, Gabbai AA et al. Assessment of Quality-of-Life and Depressive Symptoms During Long-Term Treatment with Eslicarbazepine Acetate: BIA-2093-302 study (Abstract No. 3.254). Epilepsia. 2008;49(7):455-6.

    8 Pereira H, Lopes-Lima J, Gil-Nagel A et al. Assessment of Quality-of-Life and Depressive Symptoms During Long-Term Treatment with Eslicarbazepine Acetate: BIA-2093-303 study (Abstract No. 3.240). Epilepsia. 2008;49(Suppl. 7):446-8.

    9 Cramer J, Maia J, Almeida L, et al. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate (Abstract No. T278). Epilepsia. 2009;50(Suppl. 4):124.

    10 Hodoba D, Czlonkowska A, Cramer J, et al. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate (Abstract No. T286). Epilepsia. 2009;50(Suppl. 4):126.

    CONTACTO: Contacto para prensa: Media Enquiries, EISAI (JP4523.TK)Europe Ltd,Cressida Robson, +44 7908 314 155, Cressida_Robson@eisai.net, Tonic LifeCommunications, Benjamyn Tan / Helen Swift, +44 (0)774 711 1217 / +44(0)207 798 9900, benjamyn.tan@toniclc.com, helen.swift@toniclc.com

    Relacionados

    WhatsAppFacebookFacebookTwitterTwitterLinkedinLinkedinBeloudBeloudBluesky